Gilead Sciences Partners With Vir Biotechnology in Up-to-$1.9B Solid Tumor Cancer Deal

Gilead Sciences and Vir Biotechnology announced a multi-program collaboration and license agreement to discover and develop novel PRO-XTEN dual-masked T-cell engagers targeting solid tumors, with total potential value reaching $1.9 billion. Vir will receive $90 million upfront, structured as $65 million in cash and a $25 million equity investment from Gilead at a 30% premium to Vir's market price.

The deal combines Vir's T-cell engager discovery platform, AI-enabled protein engineering, and clinically validated PRO-XTEN masking technology with Gilead's oncology development and commercialization capabilities. The PRO-XTEN masking approach is designed to improve the precision of T-cell engagers, which redirect immune cells to attack cancer, potentially reducing off-tumor toxicity in solid tumor settings.

Vir shares surged more than 11% in premarket trading following the announcement, reflecting investor enthusiasm for both the upfront payment structure and the scale of the potential milestone payments embedded in the $1.9 billion deal ceiling.